Drug-induced nephrotoxicity in inflammatory bowel disease

Nephron - Clinical Practice

Volumn 119, Issue 2, 2011, Pages

  Oikonomou, Konstantinos A ^a,b   Kapsoritakis, Andreas N ^a   Stefanidis, Ioannis ^a   Potamianos, Spyros P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b Mezourlo   (Greece)

Author keywords

Aminosalicylates; Cyclosporine; Glomerulonephritis; Inflammatory bowel disease; Nephrotoxicity; Tubulointerstitial nephritis; Tumor necrosis factor inhibitors

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PHENACETIN; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TACROLIMUS;

ACUTE KIDNEY FAILURE; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CROHN DISEASE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; ENTERIC FEEDING; ENTERITIS; FIBROSING ALVEOLITIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; ULCERATIVE COLITIS;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958768548     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000326682     Document Type: Review

References (75)

1. Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-1517. (Pubitemid 38649869)
2. Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S: Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2010 Sep 14. [Epub ahead of print] DOI: 10.1002/ ibd.21468.
3. Gisbert JP, González-Lama Y, Maté J: 5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis 2007; 13: 629-638. (Pubitemid 46799647)
4. Pardi DS, Tremaine WJ, Sandborn WJ, Mc-Carthy JT: Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93: 504-514. (Pubitemid 29080994)
5. Engel MA, Neurath MF: New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010; 45: 571-583.
6. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(suppl 5):V1-V16. (Pubitemid 39120096)
7. Reenaers C, Louis E, Belaiche J: Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol 2010; 3: 99-106.
8. de Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH: 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm Bowel Dis 2005; 11: 972-976. (Pubitemid 41580010)
9. World MJ, Stevens PE, Ashton MA, Rainford DJ: Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11: 614-621. (Pubitemid 26114541)
10. Rhodes J, Coles GA: An alternative view of 5-ASA formulations. Gut 1995; 36: 639-640.
11. Marteau P, Nelet F, Le Lu M, Devaux C: Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996; 10: 949-956. (Pubitemid 26412924)
12. Barbour VM, Williams PF: Nephrotic syndrome associated with sulphasalazine. BMJ 1990; 6: 818. (Pubitemid 20352604)
13. Thuluvath PJ, Ninkovic M, Calam J, Anderson M: Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-1496. (Pubitemid 24310920)
14. Wilcox GM, Reynolds JR, Galvanek EG: Nephrotoxicity associated with olsalazine. Am J Med 1996; 100: 238-240. (Pubitemid 126351372)
15. Dwarakanath AD, Michael J, Allan RN: Sulphasalazine induced renal failure. Gut 1992; 33: 1006-1007.
16. Masson EA, Rhodes JM: Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992; 33: 563-564.
17. Uslu N, Demir H, Saltik-Temizel IN, Topaloglu R, Gürakan F, Yüce A: Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. Dig Dis Sci 2007; 52: 2926-2929. (Pubitemid 47512516)
18. De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM: 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: Is there a link? Nephrol Dial Transplant 1997; 12: 1839-1841. (Pubitemid 27379454)
19. Popoola J, Muller AF, Pollock L, O'Donnell P, Carmichael P, Stevens P: Late onset interstitial nephritis associated with mesalazine treatment. BMJ 1998; 19: 795-797. (Pubitemid 28427238)
20. Ransford RA, Langman MJ: Sulphasalazine and mesalazine: Serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539.
21. Corrigan G, Stevens PE: Review article: Interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1-6. (Pubitemid 30058154)
22. Tadic M, Grgurevic I, Scukanec-Spoljar M, Bozic B, Marusic S, Horvatic I, Galesic K: Acute interstitial nephritis due to mesalazine. Nephrology (Carlton) 2005; 10: 103-105. (Pubitemid 40776265)
23. Stretch GL, Campbell BJ, Dwarakanath AD, Yaqoob M, Stevenson A, Morris AI, Rhodes JM: 5-Amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 1996; 10: 941-947. (Pubitemid 26412923)
24. Patel H, Barr A, Jeejeebhoy KN: Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009; 23: 170-176.
25. Van Staa TP, Travis S, Leufkens HG, Logan RF: 5-Aminosalicylic acids and the risk of renal disease: A large British epidemiologic study. Gastroenterology 2004; 126: 1733-1739. (Pubitemid 38736338)
26. Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ: Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001; 15: 1131-1137. (Pubitemid 32675446)
27. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D: Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 207-215. (Pubitemid 34146361)
28. Poulou AC, Goumas KE, Dandakis DC, Tyrmpas I, Panagiotaki M, Georgouli A, Soutos DC, Archimandritis A: Microproteinuria in patients with inflammatory bowel disease: Is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J Gastroenterol 2006; 7;12: 739-746. (Pubitemid 43380756)
29. Marcus SB, Brown JB, Melin-Aldana H, Strople JA: Tubulointerstitial nephritis: An extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008; 46: 338-341.
30. Izzedine H, Simon J, Piette AM, Lucsko M, Baumelou A, Charitanski D, Kernaonet E, Baglin AC, Deray G, Beaufils H: Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 2002; 123: 1436-1440. (Pubitemid 35231642)
31. Kreisel W, Wolf LM, Grotz W, Grieshaber M: Renal tubular damage: An extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8: 461-468. (Pubitemid 26181683)
32. Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF: Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001; 15: 363-369. (Pubitemid 32187558)
33. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48-63.
34. Sandborn WJ: Cyclosporine therapy for inflammatory bowel disease: Definitive answers and remaining questions. Gastroenterology 1995; 109: 1001-1003.
35. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 30: 1841-1845. (Pubitemid 24188135)
36. Sands BE: Immunosuppressive drugs in ulcerative colitis: Twisting facts to suit theories? Gut 2006; 55: 437-441.
37. Meijssen MA: Cyclosporine and inflammatory bowel disease: Buying time. Mediators Inflamm 1998; 7: 145-147. (Pubitemid 28338142)
38. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK: Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; 18:CD000297.
39. Stange EF, Modigliani R, Peña AS, Wood AJ, Feutren G, Smith PR: European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. The European Study Group. Gastroenterology 1995; 109: 774-782.
40. Fellermann K, Lühmann D, Stange EF: Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument. Inflamm Bowel Dis 2003; 9: 198-201; discussion 202-204. (Pubitemid 36592452)
41. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R, et al: Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 1846-1851.
42. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, de Muckadell OS, Williams N, Mac-Donald AS, Tanton R, Molina F, Campanini MC, et al: A placebo-controlled, doubleblind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 28: 845-850. (Pubitemid 19238615)
43. Sandborn WJ, Tremaine WJ, Lawson GM: Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. Am J Gastroenterol 1996; 91: 37-43. (Pubitemid 26026034)
44. Bennett WM: Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Ren Fail 1996; 18: 453-460. (Pubitemid 26240171)
45. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100. (Pubitemid 26342797)
46. Bennett WM: The nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 1996; 11: 1899-1901. (Pubitemid 26297602)
47. Shang MH, Yuan WJ, Zhang SJ, Fan Y, Zhang Z: Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity. Chin Med J (Engl) 2008; 5: 983-988.
48. Sandborn WJ: Cyclosporine therapy for inflammatory bowel disease: Definitive answers and remaining questions. Gastroenterology 1995; 109: 1001-1003.
49. Fellermann K, Lühmann D, Stange EF: Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument. Inflamm Bowel Dis 2003; 9: 198-201; discussion 202-204. (Pubitemid 36592452)
50. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease -a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-1056. (Pubitemid 43725319)
51. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T: Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 1: 589-597.
52. Blonski W, Lichtenstein GR: Safety of biologic therapy. Inflamm Bowel Dis 2007; 13: 769-796. (Pubitemid 46909994)
53. Nash PT, Florin TH: Tumour necrosis factor inhibitors. Med J Aust 2005; 15: 205-208. (Pubitemid 41150331)
54. Oikonomou KA, Kapsoritakis AN, Tsiopoulos FD, Tsikouras AN, Potamianos S: Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: A causal link or a mere coincidence? J Gastrointestin Liver Dis 2010; 19: 342.
55. Haraoui B, Krelenbaum M: Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: Possible mechanisms of action. Semin Arthritis Rheum 2009; 39: 176-181.
56. Thonhofer R, Soleiman A, Kriessmayr M, Thonhofer U, Wipfler E, Gaugg M, Eder S, Erlacher L: Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNF α therapy. Scand J Rheumatol 2006; 35: 485-488. (Pubitemid 47215709)
57. Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, Westhovens R: Benefit of anti-TNF α treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 2003; 62: 368-369. (Pubitemid 36363449)
58. Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S, Pusey CD: Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006; 17: 160-169.
59. Sakellariou GT, Vounotrypidis P, Berberidis C: Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol 2007; 26: 1132-1133. (Pubitemid 46863959)
60. den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF: Nephrotic syndrome as a complication of anti-TNF-α in a patient with rheumatoid arthritis. Neth J Med 2003; 61: 137-141. (Pubitemid 39089385)
61. Chin G, Luxton G, Harvey J: Infliximab and nephritic syndrome. Nephrol Dial Transplant 2005; 20: 2824-2826.
62. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD: Development of glomerulonephritis during anti-TNF-therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406. (Pubitemid 41430613)
63. Kemp E, Nielsen H, Petersen LJ, Gam AN, Dahlager J, Horn T, Larsen S, Olsen S: Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol 2001; 55: 87-88. (Pubitemid 32041790)
64. Mor A, Bingham C 3rd, Barisoni L, Lydon E, Belmont HM: Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005; 32: 740-743. (Pubitemid 40524710)
65. Doulton TW, Tucker B, Reardon J, Velasco N: Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004; 62: 234-238. (Pubitemid 39236628)
66. Haake H, Köneke J, Amann K, vom Dahl J, Janssen U: Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-α therapy for psoriatic arthritis. Med Klin (Munich) 2007; 15: 852-857. (Pubitemid 47619720)
67. Saint Marcoux B, De Bandt M: Vasculitides induced by TNF-α antagonists: A study in 39 patients in France. CRI (Club Rhumatismes et Inflammation). Joint Bone Spine 2006; 73: 710-713.
68. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA: Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-251. (Pubitemid 47067483)
69. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α : Findings in openlabel and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-2390.
70. Ziolkowska M, Maslinski W: Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 267-273. (Pubitemid 36532606)
71. Widemann BC, Adamson PC: Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694-703. (Pubitemid 43967624)
72. Thaunat O, Delahousse M, Fakhouri F, Martinez F, Stephan JL, Noël LH, Karras A: Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int 2006; 69: 1892-1898. (Pubitemid 43739221)
73. Babu TG, Boctor D, Davey A, Bond MC, Jacobson K: Cytomegalovirus- associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J Pediatr Gastroenterol Nutr 2004; 39: 418-421.
74. Gupta S, Weitzman S: Primary and secondary hemophagocytic lymphohistiocytosis: Clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010; 6: 137-154.
75. Lomaestro BM: Fluoroquinolone-induced renal failure. Drug Saf 2000; 22: 479-485. (Pubitemid 30386465)